info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Tetanus Toxoid Vaccine Market Size

ID: MRFR//2707-HCR | 90 Pages | Author: Kinjoll Dey| November 2024

The dynamics and growth trajectory of the Tetanus Toxoid Vaccine market are shaped by a number of factors. The increasing global awareness and focus on immunization programs are among the most significant. Governments and healthcare organizations worldwide are actively promoting vaccination campaigns to prevent tetanus, creating a significant demand for tetanus toxoid vaccines. Furthermore, increased population growth rates in developing countries coupled with an expansion in healthcare infrastructure contributes towards expanding market size.

Another pivotal factor is tetanus cases prevalence as well as effective prevention measures needed. Poorly accessed health facilities maintain Tetanus as a public health burden especially in these areas. High tetanus cases from such locales means that there is need for more vaccines on this disease prompting producers to concentrate mostly on their production and flow into the markets to meet these demands.

Besides, vaccine technology advances play a big role in shaping the Tetanus Toxoid Vaccine market. More efficient and inexpensive vaccines could emerge because of ongoing research and development efforts. Other manufacturing techniques have also been introduced such as use of new adjuvants used during vaccine production process which increases overall efficacy and safety profiles leading to changes market trends for tetanus toxoid vaccines.

Moreover, accessibility and affordability issues affect the Tetanus Toxoid Vaccine market as well. Market expansion is driven by making Vaccines available to a wider range of people including those living in third world nations. These include GAVI, the Vaccine Alliance, and government pharma collaborations aimed at providing cheap vaccines leading to an increase in supply hence increasing their market size.

In addition, regulatory frameworks and approvals significantly impact the Tetanus Toxoid Vaccine market too; stringent health authorities’ regulations; thus affecting manufacturers’ practices together with entry into markets’. This ensures that only quality products are available while building confidence amongst patients or doctors about them.

Tetanus toxoid vaccine’s competitive landscape alongside consolidation also serves as one of the determinants regarding its market dynamics. Presence of key players, mergers and acquisitions as well as strategic alliances bring about market competition. In most cases, companies engage in research and development process to be ahead in the industry thus remaining innovative leading to growth in the aforementioned markets.

Other external factors that affect the Tetanus Toxoid Vaccine market are epidemics and pandemics. The importance of vaccination during global health crises has brought more interest in vaccine discovery and distribution. For instance, the COVID-19 pandemic highlighted the role of a robust healthcare infrastructure and fast-tracked vaccine development efforts thereby indirectly affecting other vaccines such as tetanus toxoid vaccines within its broader spectrum."

Covered Aspects:

Report Attribute/Metric Details
Growth Rate   5.9%

Tetanus Toxoid Vaccine Market Overview


The Tetanus toxoid vaccine market is projected to reach USD 7,236.2 Million by 2030 at 5.9% CAGR during the forecast period 2024-2030. Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc. 


About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years. 


The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization's List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.


Tetanus Toxoid Vaccine Market


In February 2022, Ocugen, Inc. (NASDAQ: OCGN) reported that the clinical hold on the Company’s Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) had been lifted in relation to BBV152, its Covid-19 vaccine candidate referred to as COVAXIN™ abroad. The name of this covid-19 vaccine is called COVAXIN™, which is a research vaccine using vero cell production platform for whole-virion inactivated form and has been applied in manufacturing polio vaccines for years. The medicine COVAXIN™ or BBVI52 epitomizes an experimental drug in America. 


Bharat Biotech developed COVAXIN™ (BBVI52) using Indian Council of Medical Research-National Institute of Virology (ICMR-NIV). It is manufactured through vero cell culture system and it is an adsorbed killed preparation of vaccine named COVAXIN™.


In August 2022, there was a clinical trial sponsored by IBSS Biomed S.A that assessed immunogenicity as well as safety following a booster immunization with CLODIVAC bivalent vaccine against tetanus & diphtheria (IBSS BIOMED S.A.) & Td-Impfstoff Mérieux – Sanofi Pasteur among healthy adults.


On August 22th 2022 at Kamala Nehru Girls School Auditorium Bhopal, Madhya Pradesh Public Health and Family Welfare Minister set off state-level program on DPT/TD vaccination campaign.


Sanofi Pasteur joined forces with UNICEF in March 2024 to enhance availability of childhood vaccination across Africa.


Pfizer Inc., too, announced mirthful results from Phase III trials of their neoteric respiratory syncytial virus (RSV) vaccine in March 2024.


By February 2024, The Serum Institute of India had made huge financial gains due to a high demand for multiple vaccines including tetanus toxoid vaccine.


The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market. 


The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.


The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.


Intended Audience



  • Global Tetanus toxoid vaccine manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Tetanus Toxoid Vaccine Market Segment Insights


The global tetanus toxoid vaccine market is segmented on the basis of types, forms and end users. 


Tetanus Toxoid Vaccine Types Insights


Based on types, the market has been segmented as monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap) and others. 


Tetanus Toxoid Vaccine Forms Insights


Based on the forms, the market has been segmented as quadrivalent, pentavalent, and hexavalent. 


Tetanus Toxoid Vaccine End Users Insights


Based on the end users, the market has been segmented as biotech and hospitals and clinics, government organizations, research and others.


Tetanus Toxoid Vaccine Regional Insights


US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. 


The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.


Key players of Global Tetanus Toxoid Vaccine Market


Key players profiled in the report are:



  • GlaxoSmithKline Plc.

  • Merck & Co. Inc.

  • Pfizer, Inc.

  • Sanofi Pasteur, Inc.

  • AstraZeneca Plc.

  • Bharat Biotech

  • Shenzhen Kangtai Biological Products

  • Valeant Pharmaceuticals

  • Emergent Biosolutions Inc.

  • Astellas Pharma Inc.

  • Panacea Biotec

  • Others


The report for Global Tetanus toxoid vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. 


The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.